Based on our expertise in ovarian cancer we chose to study the role of FGL2 in epithelial ovarian cancer and expanded our study to compare and contrast the role of FGL2 in a common model for immunotherapy research, the B16F10 melanoma model. This evidence concerns the gene FGL2 and ovarian carcinoma.